Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Added: 3 days ago Source:  Arrhythmia Academy
A substudy of the ADVANTAGE AF trial has demonstrated that for treating typical atrial flutter (AFL), pulsed field ablation (PFA) is as effective and safe as conventional radiofrequency ablation (RFA), but significantly more efficient.¹ The study focused on adjunctive cavotricuspid isthmus (CTI) ablation, a common procedure performed during atrial fibrillation (AF) ablation.Mechanism of ActionPFA… View more
Author(s): Ahmad Masri Added: 6 months ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in… View more
Author(s): Sara Saberi Added: 6 months ago
Master the diagnostic complexities of hypertrophic cardiomyopathy (HCM) with Dr Sara Saberi, a leading expert in inherited cardiovascular diseases.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, provides essential insights into the nuanced approach required for accurate HCM diagnosis and risk stratification.Dr Saberi… View more
Author(s): Anjali T Owens Added: 6 months ago
Navigate the rapidly evolving treatment landscape for hypertrophic cardiomyopathy with Dr Anjali Tiku Owens, a renowned expert in inherited cardiovascular diseases and advanced heart failure.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, explores both established and emerging therapeutic approaches for obstructive and non… View more
Author(s): Marianna Fontana Added: 1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single… View more
Author(s): Vivek Reddy Added: 5 months ago
AHA 2025 - Dr Vivek Y Reddy (Icahn School of Medicine at Mount Sinai, New York, US) joins us to share findings from the PFA-SHAM study (NCT05717725) investigating pulsed field ablation (PFA) versus sham ablation to treat AF. Patients enrolled in the study underwent an electrophysiology study to ensure they had no concealed AV bypass tract or supraventricular tachycardia, and patients were then… View more